JOURNAL ARTICLE

'Superbabies' Startup Seeks Funds for Controversial Gene Editing Push.

  • Published In: Bloomberg.com, 2025. P. N.PAG 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Alexander, Sophie; Swetlitz, Ike 3 of 3

Abstract

The article discusses Bootstrap Bio, a California startup focused on genetically editing human embryos, which aims to create "designer babies" by altering DNA to eliminate inherited diseases or enhance traits. The technology, known as germline editing, is controversial and considered unproven and potentially dangerous by scientists and ethicists, who express concerns about its implications for safety and inequality. Bootstrap Bio's founders, Chase Denecke and Ben Korpan, shifted their focus from adult gene editing to reproductive cell modification, with early investors advocating for higher birth rates. The article also highlights regulatory challenges and the ongoing debate surrounding the ethical use of such technologies, including a call for a moratorium on germline editing practices. [Extracted from the article]

Additional Information

  • Source:Bloomberg.com. 2025/06, pN.PAG
  • Document Type:Article
  • Subject Area:Health and Medicine
  • Publication Date:2025
  • Accession Number:186161160
  • Copyright Statement:Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.